Last reviewed 2026-04-20 · How we verify

Phenpentermine (PENTOREX)

Phase 2 active Small molecule

Phenpentermine (generic name: PENTOREX) is a pentorex drug. It is currently in Phase 2 development for Weight loss.

Phenpentermine works by increasing the levels of certain neurotransmitters in the brain that help regulate appetite and metabolism.

Phenpentermine, also known as Pentorex, is a small molecule drug in the pentorex class. It is used to treat weight loss, but its target is unknown. The commercial status of Phenpentermine is unclear, and it may be patented or have generic manufacturers. Key safety considerations are not well-documented. Further research is needed to fully understand its pharmacology and safety profile.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	PENTOREX
Drug class	pentorex
Modality	Small molecule
Therapeutic area	Metabolic
Phase	Phase 2

Mechanism of action

Imagine your brain has a 'full' and 'hungry' switch. Phenpentermine helps flip the 'full' switch by increasing the levels of certain chemicals that tell your brain you're satisfied, making you eat less. This can lead to weight loss.

Approved indications

Weight loss

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Phenpentermine CI brief — competitive landscape report
Phenpentermine updates RSS · CI watch RSS

Frequently asked questions about Phenpentermine

What is Phenpentermine?

Phenpentermine (PENTOREX) is a pentorex drug, indicated for Weight loss.

How does Phenpentermine work?

Phenpentermine works by increasing the levels of certain neurotransmitters in the brain that help regulate appetite and metabolism.

What is Phenpentermine used for?

Phenpentermine is indicated for Weight loss.

What is the generic name of Phenpentermine?

PENTOREX is the generic (nonproprietary) name of Phenpentermine.

What drug class is Phenpentermine in?

Phenpentermine belongs to the pentorex class. See all pentorex drugs at /class/pentorex.

What development phase is Phenpentermine in?

Phenpentermine is in Phase 2.

Drug class: All pentorex drugs
Therapeutic area: All drugs in Metabolic
Indication: Drugs for Weight loss

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing